Susceptibility of Klebsiella pneumoniae clinical isolates from 2007 to 2009 to colistin and comparator antibiotics

International Journal of Antimicrobial Agents

Volumn 36, Issue 4, 2010, Pages 383-384

  Hawser, Stephen P ^a  

^a International Health Management Associates Europe Sàrl   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; COLISTIN; ERTAPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG SCREENING; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; COLISTIN; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS;

EID: 77955926971     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.06.004     Document Type: Letter

References (4)

1. Molina J., Cordero E., Pachón J. New information about the polymyxin/colistin class of antibiotics. Expert Opin Pharmacother 2009, 10:2811-2828.
2. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th ed. Document M7-A8. Wayne, PA: CLSI; 2008.
3. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints 2009. [accessed 17 June 2010]. http://www.eucast.org/clinical_breakpoints/.
4. Giamarellou H., Poulakou G. Multidrug-resistant Gram-negative infections: what are the treatment options?. Drugs 2009, 69:1879-1901.